The role of mRNA splicing in prostate cancer

Asian Journal of Andrology

Volumn 16, Issue 4, 2014, Pages 515-521

  Lapuk, Anna V ^a   Volik, Stanislav V ^a   Wang, Yuzhuo ^a,b   Collins, Colin C ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

alternative splicing; androgen receptor; CRPC; neuroendocrine transdifferentiation; PI3K pathway; prostate cancer; REST repressor complex

Indexed keywords

ANDROGEN RECEPTOR; CYCLIN D1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; KRUPPEL LIKE FACTOR 6; MESSENGER RNA PRECURSOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL X; RNA ISOFORM; VASCULOTROPIN;

ALTERNATIVE RNA SPLICING; CANCER CELL; CANCER CLASSIFICATION; CARCINOGENESIS; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; CELL TRANSDIFFERENTIATION; CLINICAL PATHWAY; GENE CONTROL; GENE EXPRESSION PROFILING; GENE FUNCTION; HUMAN; LIGAND BINDING; MICROARRAY ANALYSIS; NEUROENDOCRINE SYSTEM; NEUROENDOCRINE TRANSDIFFERENTIATION; PROSTATE CANCER; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; UPREGULATION;

EID: 84904731283     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.127825     Document Type: Review

References (108)

1. David CJ, Manley JL. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 2010; 24: 2343-64.
2. Chen M, Manley JL. Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat Rev Mol Cell Biol 2009; 10: 741-54.
3. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, et al. Alternative isoform regulation in human tissue transcriptomes. Nature 2008; 456: 470-6.
4. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 2008; 40: 1413-5.
5. Isken O, Maquat LE. The multiple lives of NMD factors: balancing roles in gene and genome regulation. Nat Rev Genet 2008; 9: 699-712.
6. Licatalosi DD, Darnell RB. RNA processing and its regulation: global insights into biological networks. Nat Rev Genet 2010; 11: 75-87.
7. Nilsen TW, Graveley BR. Expansion of the eukaryotic proteome by alternative splicing. Nature 2010; 463: 457-63.
8. Will CL, Lührmann R. Spliceosome structure and function. Cold Spring Harb Perspect Biol. 2011 Jul 1;3(7). pii: a003707. doi: 10.1101/cshperspect. a003707.
9. Zhou Z, Licklider LJ, Gygi SP, Reed R. Comprehensive proteomic analysis of the human spliceosome. Nature 2002; 419: 182-5.
10. Barash Y, Calarco JA, Gao W, Pan Q, Wang X, et al. Deciphering the splicing code. Nature 2010; 465: 53-9.
11. Braunschweig U, Gueroussov S, Plocik AM, Graveley BR, Blencowe BJ. Dynamic integration of splicing within gene regulatory pathways. Cell 2013; 152: 1252-69.
12. Venables JP. Aberrant and alternative splicing in cancer. Cancer Res 2004; 64: 7647-54.
13. Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 2002; 3: 285-98.
14. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314: 268-74.
15. Liu J, Lee W, Jiang Z, Chen Z, Jhunjhunwala S, et al. Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Res 2012; 22: 2315-27.
16. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, et al. Mutational landscape and significance across 12 major cancer types. Nature 2013; 502: 333-9.
17. Watson IR, Takahashi K, Futreal PA, Chin L. Emerging patterns of somatic mutations in cancer. Nat Rev Genet 2013; 14: 703-18.
18. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478: 64-9.
19. Visconte V, Makishima H, Jankowska A, Szpurka H, Traina F, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 2012; 26: 542-5.
20. Pal S, Gupta R, Davuluri RV. Alternative transcription and alternative splicing in cancer. Pharmacol Ther 2012; 136: 283-94.
21. Kalsotra A, Cooper TA. Functional consequences of developmentally regulated alternative splicing. Nat Rev Genet 2011; 12: 715-29.
22. Han H, Irimia M, Ross PJ, Sung HK, Alipanahi B, et al. MBNL proteins repress ES-cell-specific alternative splicing and reprogramming. Nature 2013; 498: 241-5.
23. Venables JP, Lapasset L, Gadea G, Fort P, Klinck R, et al. MBNL1 and RBFOX2 cooperate to establish a splicing programme involved in pluripotent stem cell differentiation. Nat Commun 2013; 4: 2480.
24. Samatov TR, Tonevitsky AG, Schumacher U. Epithelial-mesenchymal transition: focus on metastatic cascade, alternative splicing, non-coding RNAs and modulating compounds. Mol Cancer 2013; 12: 107.
25. Karamboulas C, Ailles L. Developmental signaling pathways in cancer stem cells of solid tumors. Biochim Biophys Acta 2013; 1830: 2481-95.
26. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-73.
27. Shapiro IM, Cheng AW, Flytzanis NC, Balsamo M, Condeelis JS, et al. An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet 2011; 7: e1002218.
28. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
29. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
30. Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, et al. Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet 2004; 13: 1303-13.
31. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-8.
32. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012; 44: 685-9.
33. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239-43.
34. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 2008; 13: 519-28.
35. Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 2010; 16: 793-8.
36. Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, et al. Urine TMPRSS2: ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 2011; 3: 94ra72.
37. Febbo PG, Sellers WR. Use of expression analysis to predict outcome after radical prostatectomy. J Urol 2003; 170: S11-9.
38. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412: 822-6.
39. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004; 101: 811-6.
40. Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol 2012; 227: 286-97.
41. French PJ, Peeters J, Horsman S, Duijm E, Siccama I, et al. Identification of differentially regulated splice variants and novel exons in glial brain tumors using exon expression arrays. Cancer Res 2007; 67: 5635-42.
42. Lapuk A, Marr H, Jakkula L, Pedro H, Bhattacharya S, et al. Exon-level microarray analyses identify alternative splicing programs in breast cancer. Mol Cancer Res 2010; 8: 961-74.
43. Pajares MJ, Ezponda T, Catena R, Calvo A, Pio R, et al. Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol 2007; 8: 349-57.
44. Zhang C, Li HR, Fan JB, Wang-Rodriguez J, Downs T, et al. Profiling alternatively spliced mRNA isoforms for prostate cancer classification. BMC Bioinformatics 2006; 7: 202.
45. Erho N, Buerki C, Triche TJ, Davicioni E, Vergara IA. Transcriptome-wide detection of differentially expressed coding and non-coding transcripts and their clinical significance in prostate cancer. J Oncol 2012; 2012: 541353.
46. Stephenson AJ, Smith A, Kattan MW, Satagopan J, Reuter VE, et al. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer 2005; 104: 290-8.
47. Thorsen K, Sørensen KD, Brems-Eskildsen AS, Modin C, Gaustadnes M, et al. Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol Cell Proteomics 2008; 7: 1214-24.
48. Ren S, Peng Z, Mao JH, Yu Y, Yin C, et al. RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res 2012; 22: 806-21.
49. Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 2009; 10: 981-91.
50. Dehm SM, Tindall DJ. Alternatively spliced androgen receptor variants. Endocr Relat Cancer 2011; 18: R183-96.
51. Guo Z, Yang X, Sun F, Jiang R, Linn DE, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009; 69: 2305-13.
52. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009; 69: 16-22.
53. Hu R, Isaacs WB, Luo J. A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate 2011;71:1656-67.
54. Hörnberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 2011; 6: e19059.
55. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 2012; 72: 3457-62.
56. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 2013; 73: 483-9.
57. Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, et al. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One 2011; 6: e27970.
58. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: INDUCTION of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011; 17: 5913-25.
59. Sadar MD. Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity. Cancer Res 2011; 71: 1208-13.
60. Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH, et al. Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res 2011; 71: 2108-17.
61. Nyquist MD, Li Y, Hwang TH, Manlove LS, Vessella RL, et al. TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. Proc Natl Acad Sci USA 2013; 110: 17492-7.
62. Li Y, Hwang TH, Oseth LA, Hauge A, Vessella RL, et al. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene 2012; 31: 4759-67.
63. Liu LL, Xie N, Sun S, Plymate S, Mostaghel E, et al. Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene. 2013 Jul 15. doi: 10.1038/onc.2013.284.
64. Mercatante DR, Mohler JL, Kole R. Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. J Biol Chem 2002; 277: 49374-82.
65. Savagner P, Vallés AM, Jouanneau J, Yamada KM, Thiery JP. Alternative splicing in fibroblast growth factor receptor 2 is associated with induced epithelial-mesenchymal transition in rat bladder carcinoma cells. Mol Biol Cell 1994; 5: 851-62.
66. Carstens RP, Eaton JV, Krigman HR, Walther PJ, Garcia-Blanco MA. Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. Oncogene 1997; 15: 3059-65.
67. Gnanapragasam VJ, Robinson MC, Marsh C, Robson CN, Hamdy FC, et al. FGF8 isoform b expression in human prostate cancer. Br J Cancer 2003; 88: 1432-8.
68. Lu F, Gladden AB, Diehl JA. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res 2003; 63: 7056-61.
69. Augello MA, Burd CJ, Birbe R, McNair C, Ertel A, et al. Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. J Clin Invest 2013; 123: 493-508.
70. Narla G, Kremer-Tal S, Matsumoto N, Zhao X, Yao S, et al. In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma. Oncogene 2007; 26: 4428-34.
71. Narla G, DiFeo A, Yao S, Banno A, Hod E, et al. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res 2005; 65: 5761-8.
72. Narla G, Difeo A, Reeves HL, Schaid DJ, Hirshfeld J, et al. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res 2005; 65: 1213-22.
73. DiFeo A, Martignetti JA, Narla G. The role of KLF6 and its splice variants in cancer therapy. Drug Resist Updat 2009; 12: 1-7.
74. Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 2004; 64: 7822-35.
75. Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 2008; 8: 880-7.
76. Rennel E, Waine E, Guan H, Schüler Y, Leenders W, et al. The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br J Cancer 2008; 98: 1250-7.
77. Aragon-Ching JB, Dahut WL. VEGF inhibitors and prostate cancer therapy. Curr Mol Pharmacol 2009; 2: 161-8.
78. Kumar A, White TA, MacKenzie AP, Clegg N, Lee C, et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci USA 2011; 108: 17087-92.
79. Grosso AR, Martins S, Carmo-Fonseca M. The emerging role of splicing factors in cancer. EMBO Rep 2008; 9: 1087-93.
80. van Alphen RJ, Wiemer EA, Burger H, Eskens FA. The spliceosome as target for anticancer treatment. Br J Cancer 2009; 100: 228-32.
81. Paronetto MP, Cappellari M, Busà R, Pedrotti S, Vitali R, et al. Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68. Cancer Res 2010; 70: 229-39.
82. Busà R, Paronetto MP, Farini D, Pierantozzi E, Botti F, et al. The RNA-binding protein Sam68 contributes to proliferation and survival of human prostate cancer cells. Oncogene 2007; 26: 4372-82.
83. Cappellari M, Bielli P, Paronetto MP, Ciccosanti F, Fimia GM, et al. The transcriptional co-activator SND1 is a novel regulator of alternative splicing in prostate cancer cells. Oncogene. 2013 Sep 2. doi: 10.1038/onc.2013.360.
84. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, et al. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 2007; 14: 185-93.
85. Ezponda T, Pajares MJ, Agorreta J, Echeveste JI, López-Picazo JM, et al. The oncoprotein SF2/ASF promotes non-small cell lung cancer survival by enhancing survivin expression. Clin Cancer Res 2010; 16: 4113-25.
86. Olshavsky NA, Comstock CE, Schiewer MJ, Augello MA, Hyslop T, et al. Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. Cancer Res 2010; 70: 3975-84.
87. Sette C. Alternative splicing programs in prostate cancer. Int J Cell Biol 2013; 2013: 458727.
88. Mitsiades N. A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer. Cancer Res 2013; 73: 4599-605.
89. Bitting RL, Armstrong AJ. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer 2013; 20: R83-99.
90. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011; 19: 575-86.
91. Rajan P, Dalgliesh C, Carling PJ, Buist T, Zhang C, et al. Identification of novel androgen-regulated pathways and mRNA isoforms through genome-wide exon-specific profiling of the LNCaP transcriptome. PLoS One 2011; 6: e29088.
92. Bielli P, Busà R, Paronetto MP, Sette C. The RNA-binding protein Sam68 is a multifunctional player in human cancer. Endocr Relat Cancer 2011; 18: R91-102.
93. Blaustein M, Pelisch F, Tanos T, Muñoz MJ, Wengier D, et al. Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKT. Nat Struct Mol Biol 2005; 12: 1037-44.
94. Rauch J, Moran-Jones K, Albrecht V, Schwarzl T, Hunter K, et al. c-Myc regulates RNA splicing of the A-Raf kinase and its activation of the ERK pathway. Cancer Res 2011; 71: 4664-74.
95. Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, et al. MYC and prostate cancer. Genes Cancer 2010; 1: 617-28.
96. Bernard D, Pourtier-Manzanedo A, Gil J, Beach DH. Myc confers androgen-independent prostate cancer cell growth. J Clin Invest 2003; 112: 1724-31.
97. Zhou Z, Qiu J, Liu W, Zhou Y, Plocinik RM, et al. The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus. Mol Cell 2012; 47: 422-33.
98. Bagatell R, Whitesell L. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 2004; 3: 1021-30.
99. Murphy ME. The HSP70 family and cancer. Carcinogenesis 2013; 34: 1181-8.
100. Barlow LJ, Shen MM. SnapShot: prostate cancer. Cancer Cell 2013; 24: 400.e1.
101. Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 2005; 47: 147-55.
102. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, et al. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate 2011; 71: 846-56.
103. Schoenherr CJ, Anderson DJ. The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes. Science 1995; 267: 1360-3.
104. Svensson C, Ceder J, Iglesias-Gato D, Chuan YC, Pang ST, et al. REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer. Nucleic Acids Res 2014; 42: 999-1015.
105. Chen GL, Miller GM. Extensive alternative splicing of the repressor element silencing transcription factor linked to cancer. PLoS One 2013; 8: e62217.
106. Shimojo M, Shudo Y, Ikeda M, Kobashi T, Ito S. The small cell lung cancer-specific isoform of RE1-silencing transcription factor (REST) is regulated by neural-specific Ser/Arg repeat-related protein of 100 kDa (nSR100). Mol Cancer Res 2013; 11: 1258-68.
107. Raj B, O'Hanlon D, Vessey JP, Pan Q, Ray D, et al. Cross-regulation between an alternative splicing activator and a transcription repressor controls neurogenesis. Mol Cell 2011; 43: 843-50.
108. Dehm SM. mRNA splicing variants: exploiting modularity to outwit cancer therapy. Cancer Res 2013; 73: 5309-14.